A Deeper Dive into DunedinPACE with Dr. Daniel Belsky

According to Dr. Daniel Belsky at Columbia University, there are three limitations of epigenetic biological age clocks:

1. Mortality selection
Essentially, biological age measures may underestimate true aging because older participants represent slower agers.

2. Cohort Effects
Biological age measures may overestimate true aging because older participants carry an excess burden of early-life exposure to environmental toxicants, pathogens, poor nutrition, smoking, etc.

3. Uncertain Timing
Biological age measures summarize total aging over the lifespan and cannot distinguish differences established early in development from ongoing processes of aging. As a result, biological clocks may have lower sensitivity to effects of intervention.

So, you’re probably wondering, how do we account for these limitations?

Dr. Belsky and his team have created a tool that enhances the precision of measuring the rate of biological aging. Their work involved observing the health outcomes of 954 participants across four different age groups spanning from the mid-20s to the mid-40s. The researchers examined biomarkers believed to indicate how well various organs are functioning, as well as others linked to general health. Using this data, they devised an epigenetic "speedometer" to forecast how these values would change over time.

This tool is called the DunedinPACE.

As you may already know, the DunedinPACE measures how fast you are aging biologically for every one chronological year.

In this week’s Everything Epigenetics podcast, Dan Belsky and I take a deeper dive into why Biological Age is limited and how DunedinPACE overcomes these limitations. Dr. Belsky speaks with me about a geroscience model of aging-related burden of disease, DunedinPACE test-retest reliability, and why the DunedinPACE indicates a faster pace of aging in individuals with an older chronological age.

We also discuss the effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial.

The DunedinPACE is a new tool for geoscience to investigate etiology in epidemiological studies and to evaluate the treatment effects of randomized controlled trials.

Dr. Belsky continues to validate the DunedinPACE in other populations around the world.

In this episode of Everything Epigenetics, you’ll learn about:
- Dan Belsky’s unusual journey into aging science
- How to measure aging in younger people
- A geroscience model of aging-related burden of disease
- Why it’s important to have such model
- Clinical trials which increase healthspan in animal models
- Limitations of current biological age clocks
- Mortality selection/survival bias
- Cohort effects
- Variation in biological age clocks
- The retention rate of the Dunedin study
- The fifth round measurement of the Dunedin cohort
- The range of DunedinPACE (0.6 - 1.4)
- Why we see the DunedinPACE accelerated at older chronological ages
- The CALERIE RCT
- The value of DunedinPACE
- Dr. Belsky’s focus on public health approaches to promote healthy longevity

Where to find Dr. Daniel Belsky:
Dan Belsky’s profile at Columbia University - https://www.publichealth.columbia.edu...
The Belsky Lab - https://www.belskylab.com/about
Twitter -   / danbelsky  
DunedinPACE study - https://elifesciences.org/articles/73420
CALERIE RCT - https://www.nature.com/articles/s4358...